Fucosidosis: genetic and biochemical analysis of eight cases

Helen Cragg, Magali Williamson, Elisabeth Young, John O'Brien, Jack Alhadeff, Suzanne Fang-Kircher, Eduard Paschke, Bryan Winchester

Abstract
The molecular basis of the deficiency of a-L-fucosidase has been investigated in eight patients who had been diagnosed clinically and enzymatically as suffering from the autosomal recessive lysosomal storage disease fucosidosis. None of the patients had a deletion or gross alteration of the a-L-fucosidase gene (FUCA1). Single strand conformation polymorphism (SSCP) analysis followed by direct sequencing of amplified exons and flanking regions identified putative disease causing mutations in six of the patients, who had severe forms of the disease and very low residual a-L-fucosidase activity and protein. They were a 10 bp deletion in exon 1 (E113fs), a 1 bp deletion at position -2 of intron 2 (S216fs), a g->a transition at IVS5+1, point mutations W183X and N32Y in exons 3 and 6, respectively, and a compound allele consisting of a point mutation in the signal peptide in exon PSR, and a 1 bp insertion in exon 6 (Y330fs). One patient in whom an SSCP change was not detected had residual a-L-fucosidase activity and cross reacting protein in the heterozygous range and normal metabolism of metabolites containing fucose in his fibroblasts, consistent with the low activity polymorphism. The eighth patient, who had a partial deficiency of a-L-fucosidase in her fibroblasts and leucocytes at a young age but normal a-L-fucosidase activity and protein at a later age, was homozygous for the common Q281R polymorphism in exon 5. She had no other sequence changes and Kivlin (Peters plus) syndrome has subsequently been diagnosed. The basis of her transient deficiency of a-L-fucosidase is not known. The detection of five novel mutations in six severely affected patients confirms the genetic heterogeneity in fucosidosis.

Keywords: fucosidosis; a-fucosidase; mutations.

Fucosidosis is the lysosomal storage disease resulting from a deficiency of the enzyme a-L-fucosidase (EC.3.2.1.51). 1, 2 The deficiency of this enzyme results in the accumulation in tissues and excretion in the urine of partially catabolised oligosaccharides, glycosparagines, and glycolipids with a linked fucose at the non-reducing end of the glycan chains. This accumulation leads to the clinical features, which include mental and growth retardation, neurological deterioration, coarse facies, recurrent infections, skeletal abnormalities and joint contractures, visceromegaly, hearing loss, and angiokeratoma. 3 Patients vary considerably, even within families 4 in the age of onset and severity of symptoms, indicating underlying genetic heterogeneity. There is no cure for fucosidosis, although bone marrow transplantation (BMT) was carried out recently 5 after encouraging results for BMT in the canine model of fucosidosis. 6

The α-fucosidase gene (FUCA1) has been localised to chromosome 1p36.1-1p34.1 7 and contains eight exons dispersed over 22 kb. 8 The cDNA for α-fucosidase has 2053 bp with an open reading frame for 461 amino acids including a putative signal peptide of 22 amino acids. 9, 10 A pseudogene (FUCAIL) on chromosome 2 is colinear with at least 70% of the α-fucosidase cDNA but it lacks intrinsic sequences. This permits amplification of the functional gene exons for mutation analysis using primers based on intrinsic sequences. A locus on chromosome 6 (FUCA2) linked to the plasminogen locus regulates the level of α-fucosidase in plasma 11 and fibroblasts 12 but not in leucocytes. There is no homology between FUCA1 and FUCA2. Definitive enzymatic diagnosis of fucosidosis is therefore based on measurement of α-fucosidase in leucocytes. Several putative disease causing mutations have been reported in fucosidosis. 13-23 Here, we present the biochemical characterisation and mutation analysis for eight patients who had been diagnosed enzymatically and clinically as having fucosidosis.

Methods
PATIENTS
All the patients had been diagnosed as having fucosidosis by the finding of decreased a-L-fucosidase activity in white blood cells, fibroblasts, or serum to confirm a preliminary clinical diagnosis. Details of the patients are given in table 1 and in the Discussion.

ASSAY OF a-FUCOSIDASE ACTIVITY IN FIBROBLASTS AND LEUCOCYTES
Leucocytes were isolated from heparinised blood and cultures of skin fibroblasts established as described previously. 24 Lymphoblastoid cell lines were established by viral transformation at the National Microbiological Research Centre, Porton Down, Wiltshire, UK. The α-fucosidase activity was measured in...
all cells using the synthetic fluorogenic substrate, 4-methylumbelliferyl α-L-fucoside.18

**QUANTITATIVE MEASUREMENT OF α-FUCOSIDASE PROTEIN BY A DOUBLE ANTIBODY SANDWICH ELISA TECHNIQUE**

Fifty microlitres of a solution of polyclonal goat anti-human α-L-fucosidase IgG25 (20 μg/ml) in PBS was put in the well of a microtitre plate with 50 μl PBS in control wells. The plates were incubated at room temperature for 1.5 hours. The wells were washed twice with PBS and then 250 μl of blocking solution (BSA 3%) (w/v) in sodium azide 0.02% (w/v)) was added to each well. The plates were incubated at room temperature overnight and then washed twice with PBS. Then 50 μl of extracts of sonicated fibroblasts or lymphoblasts which had been diluted to 20 μg/ml, 40 μg/ml, or 80 μg/ml in blocking solution were added with PBS in the control wells. The plates were incubated for 1.5 hours at room temperature then washed four times with PBS.

Fifty microlitres of monoclonal rat anti-human α-L-fucosidase IgG28 diluted 1000 fold in blocking solution, was then added, again using PBS as control. After incubation for 1.5 hours at room temperature the wells were washed four times with PBS. Then 100 μl of alkaline phosphatase conjugated goat anti-(rat IgG serum), diluted 500 times in blocking solution, was added to each well. The plates were incubated for one hour and then washed four times with PBS, followed by twice with 10 mmol/l diethanolamine, pH 9.5, containing 0.5 mmol/l MgCl2. Then 50 μl of substrate solution, 1 mg/ml p-nitrophenyl phosphate in 10 mmol/l diethanolamine, was added to each well and the plates were incubated for two hours or overnight at room temperature. The absorbance at 405 nm of the released p-nitrophenol was measured using an ELISA plate reader.

**SOUTHERN BLOT ANALYSIS**

Radiolabelled α-fucosidase cDNA probes and genomic DNA were prepared and used for Southern blot analysis as described previously.19

**POLYMERASE CHAIN REACTION (PCR)**

Exons 1 to 8 of the α-fucosidase gene were amplified by PCR using the primers and conditions listed in tables 2 and 3.19 Radiolabelled amplification products were obtained by the incorporation of α-32P-dCTP during the amplification reaction. The amplified product of exon 1 (513 bp) was digested to fragments of 194 and 319 bp with the restriction enzyme NcoI before SSCP analysis.

**SINGLE STRANDED CONFORMATIONAL POLYMORPHISM (SSCP) ANALYSIS**

Radiolabelled PCR products were denatured at 94°C for five minutes and then analysed by electrophoresis in a 6% non-denaturing polyacrylamide gel for 14 to 18 hours at 4°C or room temperature and the bands detected by autoradiography.19, 27

**SEQUENCING OF PCR AMPLIFIED PRODUCTS**

The amplified products of each exon were sequenced by a number of methods. Exons 2, 5, 7, and 8 were sequenced using the Dynal products.

### Table 2 Primers used for PCR

<table>
<thead>
<tr>
<th>Primer number</th>
<th>Primer sequence</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>5' GCC GCC GCC GCC CAC CTG GGG CTT AA 3'</td>
<td>5' untranslated</td>
</tr>
<tr>
<td>2</td>
<td>5' GCC GCC GCC CAC CTC CTG 3'</td>
<td>Intron 1</td>
</tr>
<tr>
<td>3*</td>
<td>5' TCA GGG ATG CTG GGC AAC TTA A 3'</td>
<td>Intron 1</td>
</tr>
<tr>
<td>4</td>
<td>5' GAG GAG GTA CAG AAC TCT TGA CAG 3'</td>
<td>Intron 2</td>
</tr>
<tr>
<td>5*</td>
<td>5' AAT GGT TTA TAA TAT ACT GCT AAC 3'</td>
<td>Intron 3</td>
</tr>
<tr>
<td>6</td>
<td>5' TTA ATG GTA CCC TAT AGG AAG 3'</td>
<td>Intron 3</td>
</tr>
<tr>
<td>7*</td>
<td>5' AAT GGT CTA TAA TAT ACT GCT AAC 3'</td>
<td>Intron 3</td>
</tr>
<tr>
<td>8</td>
<td>5' ACT CCA GAG TGT GGA TGC TTA 3'</td>
<td>Intron 4</td>
</tr>
<tr>
<td>9*</td>
<td>5' GAT GAG GTG GTA GTA AAT GA 3'</td>
<td>Exon 5</td>
</tr>
<tr>
<td>10</td>
<td>5' AAA TTA TTT CAG ATT CCT C 3'</td>
<td>Exon 5</td>
</tr>
<tr>
<td>11*</td>
<td>5' GCT TGC TGG TGC ATT GY 3'</td>
<td>Intron 4</td>
</tr>
<tr>
<td>12</td>
<td>5' AGC TTT TGA ACA TTA TAT 3'</td>
<td>Intron 5</td>
</tr>
<tr>
<td>13*</td>
<td>5' TAA GCA TTA TGC GCT CTG 3'</td>
<td>Intron 5</td>
</tr>
<tr>
<td>14</td>
<td>5' AGG AGA TAC CAG TTT GTC CGT 3'</td>
<td>Intron 6</td>
</tr>
<tr>
<td>15*</td>
<td>5' GGA GAA GTA TAA AGT TGT ATA TCA 3'</td>
<td>Intron 6</td>
</tr>
<tr>
<td>16</td>
<td>5' AGG GAA GGA AGA GAA GGA T 3'</td>
<td>Intron 7</td>
</tr>
<tr>
<td>17*</td>
<td>5' TCC TGC ATG AGT CCT GCT 3'</td>
<td>Intron 7</td>
</tr>
<tr>
<td>18</td>
<td>5' AAA CAC TGA GCA GCC CAC CT 3'</td>
<td>3 non-coding</td>
</tr>
</tbody>
</table>

* Biotinylated.

### Table 3 Conditions for PCR

<table>
<thead>
<tr>
<th>Exon number</th>
<th>Primer pair</th>
<th>PCR product (bp)</th>
<th>Annealing temp (°C)</th>
<th>DMSO (mmol/l)</th>
<th>Mg++ (mmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1, 2</td>
<td>194, 319*</td>
<td>70</td>
<td>10%</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>2, 3</td>
<td>275</td>
<td>70</td>
<td>5.6</td>
<td>1.5</td>
</tr>
<tr>
<td>3</td>
<td>3, 4</td>
<td>290</td>
<td>50</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>4, 5</td>
<td>198</td>
<td>70</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>5</td>
<td>5, 6</td>
<td>201</td>
<td>49</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>6</td>
<td>6, 7</td>
<td>538</td>
<td>49</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>7</td>
<td>7, 8</td>
<td>315</td>
<td>57</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>8</td>
<td>8, 9</td>
<td>249</td>
<td>61</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>9</td>
<td>9, 10</td>
<td>257</td>
<td>60</td>
<td>1.5</td>
<td>1.5</td>
</tr>
</tbody>
</table>

* After digestion with NcoI.
† Exonic primers.
streptavidin bead technology as previously described.18 Exon 3 was analysed using the Stratagene Cyclist Exo-pfu DNA sequencing kit according to the manufacturer’s instructions; 200 fmol of PCR product was sequenced using 1 pmol of primer incorporating 10 μCi of α32P-dATP and 2.5 units of Exo-pfu polymerase. The temperature programme used for sequencing was the same as that used for the initial PCR amplification. Exons 1 and 6 were cloned into the pGEM-T vector (Promega) according to the manufacturer’s instructions. The nucleotide sequence of the inserts was determined by the dideoxy nucleotide chain termination method. Nucleotide sequences were obtained from three independent PCR amplification reactions.

**Results**

**Southern blot analysis**

Genomic DNA from the patients was analysed by Southern blotting to detect any gross gene rearrangements and to determine the haplotype of the patient for two common restriction fragment length polymorphisms observed after digestion with PvuII and BglII (table 4). No gross gene deletions or rearrangements were observed using a panel of restriction enzymes indicating that the mutations were either microdeletions, microinsertions, or point mutations. This excluded the occurrence of the previously described large deletion of the 3′ end of the genes.3 A specific change in the band pattern was observed for DNA from patient 2 on digestion with TaqI. This has been shown previously by us to result from a mutation in the 5′ splice site of intron 5.19

The recurrent mutation Q422X, which has been found in 10 patients with the haplotype (2-2) (2-2) (table 4) from six unrelated families15 was not detected by Southern blotting in our patients 3 and 7 with the same haplotype. This was confirmed by the specific amplification of exons 7 and 8 using primers 15 and 18 in intron 6 and in the 3′ non-coding region, respectively (table 1), and subsequent digestion with EcoRI.

**Detection of sequence changes by SSCP**

The eight exons of FUCA1 and their flanking regions were amplified from genomic DNA from patients and controls by PCR using pairs of intronic primers (tables 2 and 3). Amplified material of the expected sizes was obtained for each exon from all the patients, confirming that no gross deletions of the gene were present. These observations, together with the results of Southern blot analysis, suggest that the mutations in the patients are single base changes or small insertions or deletions.

The radiolabelled PCR products were analysed directly by SSCP, except for the PCR product of exon 1, and altered band patterns were observed in seven out of eight of the patients, patient 1 being the exception. Patients 3 and 7 appeared to be homozygous and patient 5 heterozygous for the characteristic band pattern associated with the polymorphism Q281R.20 This was the only abnormal pattern seen for patient 7. Surprisingly only one patient, patient 6, showed conformational changes in more than one exon (excluding the Q281R polymorphism). This suggested that either the patients were homozygous for a single sequence change or that two different allelic changes occurred in the same exon but the SSCP band patterns were not complex enough for the latter explanation. It is also possible that other sequence changes did not produce a conformational change detectable under the conditions used. Thus non-polymorphic sequence changes were detected in all the patients except patients 1 and 7.

**Detection of mutations by sequencing**

The PCR products showing SSCP changes were sequenced and sequence changes were detected in all the products analysed (table 1). All the sequence changes were present in a homozygous form including those in patient 6, who had sequence changes in both exons 1 and 6. No other sequence changes were detected in the amplified exons that were sequenced apart from the CG transversion in exon 5 responsible for the Q281R polymorphism. In some cases, exons in which an SSCP change had not been detected were sequenced but no further sequence changes were found.

Several of the sequence changes abolished or created sites for restriction enzymes in the amplified sequences, permitting confirmation of the presence of the mutations by restriction analysis (table 1). The PSR mutation was shown to be homozygous in patient 6 and heterozygous in both his parents by digestion with HaeIII. A unique HindI site is created by the W183X mutation in patient 5 and this was exploited to confirm the homozygosity of this mutation in the patient. The splice site mutation in the 5′ splice of intron 5 in patient 2 can be detected because it creates a new TaqI site. This mutation was first detected by Southern blotting using this enzyme and can be readily detected by amplifying exon 5 and its flanking regions followed by digestion with TaqI.19 The presence of the Q281R polymorphism was also confirmed in patients 3, 5, and 7 by digestion of exon 5 with BglII.21

**Effect of mutations on α-fucosidase**

The α-fucosidase activity in fibroblasts from the patients was measured using the synthetic fluorogenic substrate, 4-methylumbelliferyl α-L-fucopyranoside (table 1). The two patients, 1 and 7, in whom an SSCP change had not been detected had activities well within or

---

**Table 4 Haplotypes for PvuII and BglII polymorphisms**

<table>
<thead>
<tr>
<th>Patient</th>
<th>PvuII</th>
<th>BglII</th>
<th>Haplotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>2</td>
<td>1-1</td>
<td>1-1</td>
<td>(1-1)(1-1)</td>
</tr>
<tr>
<td>3</td>
<td>2-2</td>
<td>2-2</td>
<td>(2-2)(2-2)</td>
</tr>
<tr>
<td>4</td>
<td>1-1</td>
<td>1-1</td>
<td>(1-1)(1-1)</td>
</tr>
<tr>
<td>5</td>
<td>N/A</td>
<td>1-2</td>
<td>N/A</td>
</tr>
<tr>
<td>6</td>
<td>1-1</td>
<td>2-2</td>
<td>(1-2)(1-2)</td>
</tr>
<tr>
<td>7</td>
<td>2-2</td>
<td>2-2</td>
<td>(2-2)(2-2)</td>
</tr>
<tr>
<td>8</td>
<td>N/A</td>
<td>1-1</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Band sizes seen on Southern blot. PvuII 1 = 7.0 kb; 2 = 6.0 kb. BglII 1 = 12.0 kb, 2 = 6.5 kb + 5.5 kb.
at the bottom of the normal reference range, respectively. In contrast, the six patients in whom a putative mutation had been found had α-fucosidase activity well below the normal reference range. These results suggest that the detected sequence changes had decreased the α-fucosidase activity.

The amount of protein cross reacting with antibodies raised against purified human liver α-fucosidase was measured in two of the fucosidosis patients with negligible residual activity, 4 and 6, and in the two patients, 1 and 7, with high residual activity, using a double antibody ELISA method (table 1). Patients 4 and 6 had very low concentrations of cross reacting material, 7.5 and 6.9% of the mean measured in controls, respectively. Willems et al26 found the residual α-fucosidase protein to be below 6% of the normal mean in lymphoblastoid cells of 23 fucosidosis patients. Patient 1 had an intermediate level of CRIM (36% of control fibroblasts) and patient 7 a normal level.

Discussion

Two patients were homozygous for missense mutations. The N329Y mutation in patient 8 substitutes a tyrosine for an asparagine residue that is conserved in α-fucosidases from human, rat and Dicistrostemis discoideum,27 and dog.28 The change from a small neutral to a larger hydrophobic side chain would be expected to disrupt the conformation of this highly conserved region and to affect the α-fucosidase activity. Asparagine 329 is not part of an N-glycosylation sequon. Patient 8 had a severe form of the disease dying at 3 years 4 months but with initial mild symptoms followed by a rapid and fatal deterioration.32

Patient 6 was homozygous for a missense mutation, PSR, in exon 1 and a single base insertion in exon 6 (Y330Ps). Both his parents are heterozygous for the two mutations, indicating that they are on the same chromosome. Substitution of the neutral and non-polar amino acid, proline, by the basic and polar amino acid, arginine, would be expected to alter the folding or chemical topography of the polypeptide chain. This substitution is at the first residue of the hydrophobic core of the 22 amino acid signal peptide of α-fucosidase and might be expected to impair the translocation of the nascent preproenzyme through the endoplasmic reticulum membrane. The effect of a mutation in the signal peptide sequence on the intracellular transport of a lysosomal enzyme is not well understood because such mutations are not common. A missense mutation, A20P, in the signal peptide of α-galactosidase has been shown to lead to a moderate decrease in mRNA in an atypical variant of Fabry disease33 and a 1 bp deletion at codon 15 in the signal peptide sequence of iduronate 2-sulphatase has been reported to lead to a mild form of Hunter disease.34 At least three non-pathogenic polymorphisms have been found in the signal peptide sequence of α-L-iduronidase35 and it has been suggested that such polymorphisms may contribute to the normal variation in enzymatic activity or exacerbate the effect of another sequence change in the gene. The other sequence change in the compound mutant allele of patient 6 is the insertion in exon 6 of a thymine leading to a frameshift and the formation of a premature stop codon, TAA, nine amino acids downstream within the exon. This change could lead to loss of enzymatic activity either by the formation of a truncated protein or by exon skipping. Although patient 6 had severe symptoms he survived to 15 years, suggesting that the low residual activity and cross reactions material (6.9%) produced by this compound allele was partially effective. The g→a transition at the +1 position of the 5' donor splice site of exon 5 in patient 2 was shown to be homozygous by family studies.35 Both parents, who are distantly related, were carriers of the mutation, which cosegregated with the fucosidosis allele in other family members, indicating strongly that this is the disease causing mutation in this family. Calculation of the likelihood of the use of the normal and mutant splice sites, according to Shapiro and Senepathy,36 indicated that the mutation would lower the likelihood score from 86 to 68. Analysis of the sequence of exon 5 did not show any cryptic splice sites with a higher probability of usage than the mutated splice site. Therefore, exon 5 would probably be spliced out leading to a frameshift in the truncated protein from the 5' donor splice site, both of which would explain the deficiency of α-fucosidase. The patient is now aged 13.5 years but is deteriorating rapidly.

The second identified splice site mutation was deletion of adenine at position -2 of intron 2 (S216fs) in patient 4. This mutation, which was homozygous in the patient, was predicted to have two possible effects. Firstly, it may affect splicing, but the likelihood score for the use of the splice site only decreased from 94 to 87, suggesting that the alteration to the reading frame would be more important. The frameshift changes the amino acid sequence from SYKPDL to AINLITERM, that is, the creation of a premature stop codon 5 amino acids downstream from the affected codon. Homozygosity for this mutation resulted in very little residual enzymatic activity and protein (7.5%) and a severe form of the disease. This mutation has been found in a heterozygous state in a Belgian patient,37 in whom the other mutation is unknown.

Patient 5 is homozygous for the nonsense mutation, W183X, which could result in a truncated protein or, more likely, a severe decrease in the level of mRNA. There is negligible α-fucosidase in fibroblasts from this patient, who was severely physically and mentally retarded at the age of 7 years but who did not deteriorate significantly over the next two years.38

The 10 bp deletion in exon 1 (E113fs), which is homozygous in patient 3, also results in a premature termination codon, in frame, 10 amino acids downstream from the beginning of the deletion in codon 114. A three base pair repeat of GAG or GGA involving the first two of the deleted base pairs could be the cause of
Molecular basis of fucosidosis

Putative disease causing mutations have been discovered in six out of eight patients, who were diagnosed clinically and biochemically as having fucosidosis. The absence of common mutations and the differences in clinical phenotype of patients with negligible residual α-fucosidase activity confirm the heterogeneity in this disorder. All the patients were homozygous for different single mutations or in one case for an allele with two sequence changes. In some cases, it was possible to attribute this homozygosity to consanguinity or to substantiate it by family studies. The five new mutations discovered in this study bring to 20 the number of putative disease causing mutations found in patients with fucosidosis.

We would like to thank Dr Michael Cantis (Heidelberg) for referring patient 1 and his colleague Barbara Ulrich-Bott for carrying out the metabolic studies on the fibroblasts of patient 1, and Professors Jane Lande, Ian Yovich and Judith Grant for referring patients 7 and 2, respectively. Helen Craig and Magali Williamson thank the Child Health Research Appeal Trust and the Biotechnology and Biological Sciences Research Council (formerly SERC), respectively, for postgraduate studentships. The support of the Society for Mucopolysaccharide Disease is also acknowledged and we thank Dr Sue Malcolm for her advice during this project.

Fucosidosis: genetic and biochemical analysis of eight cases.

H Cragg, M Williamson, E Young, J O'Brien, J Alhadeff, S Fang-Kircher, E Paschke and B Winchester

J Med Genet 1997 34: 105-110
doi: 10.1136/jmg.34.2.105

Updated information and services can be found at:
http://jmg.bmj.com/content/34/2/105

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/